Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases.

Haematologica
Carole SoussainVéronique Leblond

Abstract

Relapsing primary central nervous system lymphoma carries a poor prognosis when treated with conventional chemotherapy with a one-year overall survival of 25-40%. Encouraging results have been shown with intensive chemotherapy followed by autologous hematopoietic stem cell rescue. We report the results of a large multicenter retrospective analysis of intensive chemotherapy followed by hematopoietic stem cell rescue in immunocompetent adult patients with primary central nervous system lymphoma or intraocular lymphoma after the failure of high-dose methotrexate-based treatment. Patients were included if they received intensive chemotherapy with a combination of thiotepa, busulfan and cyclophosphamide. Seventy-nine patients (median age 52.4 years, range 23-67 years) were identified. All of the patients except 5 received a salvage treatment after the failure of high-dose methotrexate. After salvage treatment and just before intensive chemotherapy followed by hematopoietic stem cell rescue, 32 patients were in complete response, 26 patients were in partial response, 2 patients had stable disease and 19 patients had progressive disease. With a median follow up of 56 months, the 5-year overall survival probability was 51% in the whole...Continue Reading

References

Sep 10, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Scott R PlotkinTracy T Batchelor
Mar 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul L NguyenJay S Loeffler
Jun 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lauren E AbreyUNKNOWN International Primary CNS Lymphoma Collaborative Group
Apr 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carole SoussainUNKNOWN Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire
May 13, 2009·The Oncologist·Monica Sierra del RioKhê Hoang-Xuan
Jul 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian GisselbrechtNorbert Schmitz

❮ Previous
Next ❯

Citations

Apr 9, 2013·Current Neurology and Neuroscience Reports·Mariza Daras, Lisa M DeAngelis
Feb 20, 2014·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Noriyasu HashidaKohji Nishida
Jun 28, 2014·Current Hematologic Malignancy Reports·Elizabeth H PhillipsKate Cwynarski
Jul 13, 2014·Neuro-oncology·Lisa M DeAngelis
Sep 16, 2015·Expert Opinion on Pharmacotherapy·Giovanni CitterioAndrés José Maria Ferreri
Sep 16, 2015·Current Opinion in Oncology·Andreas F HottingerKhê Hoang-Xuan
Jul 8, 2015·The Lancet Oncology·Khê Hoang-XuanUNKNOWN European Association for Neuro-Oncology Task Force on Primary CNS Lymphoma
May 15, 2015·Indian Journal of Ophthalmology·Kaustubh MulaySantosh G Honavar
Feb 25, 2014·Survey of Ophthalmology·Mandeep S SagooSue Lightman
Mar 16, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Agnieszka KorfelPhilipp Kiewe
Apr 11, 2018·Expert Review of Neurotherapeutics·Giovanni CitterioAndrés J M Ferreri
May 29, 2018·British Journal of Haematology·Christian Gisselbrecht, Eric Van Den Neste
Nov 24, 2018·British Journal of Haematology·Christopher P FoxUNKNOWN British Society for Haematology
Jan 24, 2019·International Journal of Hematology·Daria Gaut, Gary J Schiller
Oct 9, 2019·Expert Review of Anticancer Therapy·Sabine Seidel, Uwe Schlegel
Feb 21, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Caroline HouillierUNKNOWN Intergroupe GOELAMS–ANOCEF and the LOC Network for CNS Lymphoma
May 16, 2018·International Journal of Retina and Vitreous·Jose S PulidoHarish Raja
Sep 10, 2020·Frontiers in Oncology·Tongjuan LiXiaoxi Zhou
Mar 1, 2017·Neuro-oncology Practice·Agnieszka KorfelTakanori Hirose
Jul 13, 2018·Deutsches Ärzteblatt International·Louisa von BaumgartenMartin Dreyling
Oct 23, 2020·The British Journal of Ophthalmology·Mona MohammadMandeep S Sagoo
Feb 15, 2020·Survey of Ophthalmology·Alexandra L Farrall, Justine R Smith
May 18, 2021·Frontiers in Oncology·Kaiyan TaoXin Tian
Aug 28, 2021·British Journal of Haematology·Nicolas Martinez-CalleElisabeth Schorb
May 27, 2021·Blood·Carole SoussainNathalie Cassoux

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Journal of Neuro-oncology
K JahnkeGerman Primary Central Nervous System Lymphoma Study Group
Current Treatment Options in Oncology
Stephane DoucetJ Raizer
Journal of Ophthalmic Inflammation and Infection
Daniel Vítor Vasconcelos-SantosFernando Oréfice
© 2021 Meta ULC. All rights reserved